Table 2 Patient co-morbidities across DREAM, MENSA, SIRIUS, and MUSCA
From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
|  | Patients (N = 1878) |
|---|---|
Any condition, n (%) | 1569 (84) |
Upper respiratory, n (%) | Â |
 Any condition | 1102 (59) |
 Allergic rhinitis or hay fever | 911 (49) |
 Sinusitis | 288 (15) |
 Nasal polyps | 293 (16) |
Cardiovascular, n (%) | Â |
 Any condition | 620 (33) |
  Arrythmia | 49 (3) |
 Cardiac failure | 13 (< 1) |
 Cardiomyopathy | 4 (< 1) |
 Coronary artery disease | 48 (3) |
 Hypertension | 560 (30) |
 Hyperglycemia | 48 (3) |
 Cerebrovascular disorder | 7 (< 1) |
 Thrombophlebitic event | 4 (< 1) |
Obesitya, n (%) | 603 (32) |
Gastroesophageal reflux, n (%) | 400 (21) |
Psychopathologies, n (%) | Â |
 Any condition | 326 (17) |
 Anxiety | 141 (8) |
 Depression | 149 (8) |
 Mood changes | 78 (4) |
 Sleep disorders | 158 (8) |
Diabetes mellitus, n (%) | 148 (8) |
Vocal cord dysfunction, n (%) | 14 (< 1) |